INTRODUCTION
O besity is an international health problem, with high morbidity and mortality 1 . Worldwide, more than two million people die annually due to obesity or overweight 2 .
The higher the body mass index (BMI), the greater the risk of comorbidities 2 . Overall, mean BMI has increased by 0.4kg/m 2 per decade 3 . In Brazil, obesity affects 17.5%
of the population and the prevalence of morbid obesity (BMI≥40kg/m 2 ) increased by more than 255% since High-risk morbid obese individuals are usually defined by superobesity (SO), BMI=50kg/m 2 , associated with males, age >45 years and presence of severe comorbidities. Such a population represents a challenge in bariatric surgery due to technical difficulties, high mortality rates, and perioperative morbidity, which reach 12% and 40%, respectively, in the early postoperative period 8 . In fact, the 30-day mortality risk increases exponentially according to the number of comorbidities in these patients: 0-1 comorbidities: 0.03%; 2-3 comorbidities; 0,16%; and 4 comorbidities: 7,4 % 9 .
To minimize this risk, a significant loss of preoperative weight is essential. Currently, the viable strategies to achieve it are hypocaloric diet, medications, hospitalization and Intragastric Balloon (IGB) 8, 10 . However, the low calorie diet has a considerable circumvention rate, most anti-obesity drugs have been withdrawn from the market due to systemic side effects and hospitalization for an intensive program in a controlled environment is excessively onerous 10 . Thus, IGB have been widely used as a bridge for bariatric surgery in high-risk superobese patients. Generally, the established goal is 10% excess weight loss (10% EWL) 10 , with positive effects on postoperative risk, technical complexity and shorter surgical times due to a decrease in the volume of the liver and adipose, subcutaneous and visceral tissues 11 , and may improve the results of surgery after one year 12 . The degree of risk reduction seems to relate to the degree of weight loss, and patients with higher BMIs probably benefit more 13 .
In six months, IGB generally reach the goal of 10% EWL or more, providing greater control of obesity-related diseases and improvement in metabolic profile, without compensatory increase of appetite hormones 10, [14] [15] [16] . In fact, it is considered a safe procedure with few complications. Serious events are exceptional 17 .
Perforation, the most feared, can occur in the stomach (0.2%) or more rarely in the esophagus, subsequent to implantation or endoscopic extraction [18] [19] [20] . 23 .
In this study, our objective is to identify the short-term efficacy of IGB in the treatment of high-risk morbid obesity patients in a bridge-to-surgery strategy, assessing their tolerance and complications at our center.
METHODS
This is a post-hoc study-analysis from June 2010 to June 2014, at a public hospital in Fortaleza-CE. The institutional Ethics Committee approved the research protocol (Number 831,224), with written consent of the patients and the hospital for access to medical records. Participants included high-risk, morbidly obese adult patients who were refractory to conservative treatment, were involved in the weight loss program, and underwent IGB insertion as a bridge to bariatric surgery. We excluded individuals with BMI<48kg/m 2 or with balloon contraindications. Each patient received a single balloon, which could be filled with 500cc of air or 500-700 cc of liquid. Until October 2012, we implanted air IGB, and liquid ones thereafter, due to changes in the availability of these devices in the hospital. The insertion of IGB occurred with conscious sedation assisted by an anesthesiologist and removal under general anesthesia under direct endoscopic control, using gastroscopes and standard accessories (needle catheter, grasping clamps and polypectomy loops). We performed a routine upper digestive endoscopy before IGB implantation.
The preoperative weight loss protocol consisted of multidisciplinary outpatient follow-up (with surgeons, internists, nutritionists, psychologists and psychiatrists), IGB implantation, hypocaloric diet (1000 cal/day) and physical activities. In addition, there were regular consultations with the bariatric endoscopist for assessment of efficacy and tolerance, weekly in the first month post-procedure, fortnightly in the second month, and monthly thereafter. We prescribed proton pump inhibitors during the IGB permanence, associated with antiemetics and analgesics during the first two weeks.
All patients had their weight monitored before IGB implantation, at each follow-up visit and at extraction. Using standard methods of weight loss quantification 24 , such as Ideal weight corresponding to BMI 25kg/m 2 and % EWL, we defined the efficacy as at least 10% EWL.
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and expressed results as mean ± standard deviation. We used the paired T and Student's T tests, as appropriate, for comparison between groups. We set the statistical significance at p<0.05.
RESULTS
Twenty-three patients received IGB and their characteristics are shown in table 1. The main comorbidities at the beginning of treatment were hypertension, sleep apnea syndrome and diabetes.
We considered complications as adverse effects attributable to IGB diagnosed after two weeks of insertion, identified during the outpatient follow-up.
In our experience, nausea, vomiting and abdominal pain are very common in such a period, consequent to gastric accommodation to the foreign body, and easily treated with oral medication. Therefore, we did not consider such complications in this study.
The studied variables included IGB type, length of stay, associated complications, % EWL, weight variation and BMI. We used used SPSS 20 to process the data, There was no difference between the two types of balloons in relation to the final weight parameters.
As described in table 3, our complication rate was 17.3%, including abdominal discomfort (8.7%), balloon deflation with migration (4.3%), and late intolerance with severe dehydration (4.3%). Cases of abdominal discomfort were mild, patients were treated conservatively and experienced gradual symptom resolution. On the other hand, the patient with balloon deflation had migration to the small intestine and obstruction, being submitted to surgery for removal of the device. Interestingly, the IGB had remained in situ during the six-month period. One late intolerance 
DISCUSSION
There are several studies of IGBs with heterogeneity in BMI the selection criteria. Most of them define the lower limit of BMI at 40kg/m 2 , with weight losses ranging from 17 to 21kg 16, [25] [26] [27] [28] . Much of the published data refers to Orbera's IGB, while there is a relative paucity of articles on Heliosphere 29 , a 30g silicone-coated polymer with two layers interconnected by a valve, unlike most liquid IGBs, which are also made of silicone but weigh 500-600 g 23, 30 . Our overall complication rate was 17.3%.
The literature cites a range of possible complications:
intolerance with early removal (up to 6.3%), deflation and migration (1.6-28.9%), abdominal pain (5.8-11.6%), nausea and vomiting (up to 18%), minor side effects (0.2-1.27%) and some rare reports of fatalities (0.07%) 23, 30, 39, 42 . In our study, we observed a 4.3% rate . The longer it remains in situ, the greater the likelihood of damage, such as erosions on the silicone surface 43 .
Diagnosing a leakage of liquid IGB is relatively simple, given the urine of bluish coloration, because of the excretion of methylene blue. However, diagnosing the spontaneous rupture of an air IGB is a challenge, since it is usually an asymptomatic process. Frequently, one can only detect subsequent complications, such as mechanical ileus or perforations 45 .
In conclusion, the current efficacy of intragastric balloons in high-risk obese patients at our center is 91.3%, with clinical success and satisfactory tolerance. Our complication profile is within published rates. Intragastric balloons can be used effectively, in association with diet, as a bridge to surgery in our center.
Objetivo: identificar a eficácia em curto prazo, a tolerância e as complicações em obesos mórbidos de alto risco, tratados com balão intragástrico como ponte para cirurgia. 
